Skip to content

Tofacitinib for the treatment of moderate-to-severe psoriasis

Tofacitinib for the treatment of moderate-to-severe psoriasis. Expert Rev. Clin. Immunol. 11(4), 443455 (2015). Andrea Chiricozzi1,2,. Sara Faleri1,. Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis V Di Lernia,1 F Bardazzi2 1Dermatology Unit, Arcispedale Santa Maria Nuova IRCCS, Reggio Emilia, 2Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy Abstract: The outlook for patients with psoriasis has improved significantly over the last 10 years with the introduction of targeted therapies. However, these treatments often fail to adequately prevent disease progression. In a phase IIa clinical trial, Ports et al (2013) evaluated the safety, effectiveness, local tolerability and systemic pharmacokinetics of topical tofacitinib in mild-to-moderate plaque psoriasis.

Tofacitinib for the treatment of moderate-to-severe psoriasis 2 Apremilast is a novel oral agent of the phosphodiesterase type 4 (PDE4) class approved in 2014 for the treatment of moderate to severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy. 12 Based on concern about potential safety issues, FDA rejected a supplemental new drug application submitted this past October highlighting tofacitinib’s expanded use in psoriasis.13 Tofacitinib may receive FDA approval at a later date following the release of more long-term safety data. Tofacitinib (INN) is a drug of the janus kinase (JAK) inhibitor class, discovered and developed by the National Institutes of Health and Pfizer. It has demonstrated effectiveness in the treatment of psoriasis in Phase 3 studies. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Psoriatic arthritis Psoriasis Biologic treatments Small molecule inhibitors Level of evidence of biologic agents efficacy. There is no published date for tofacitinib in the treatment of PsA, but clinical trials are currently ongoing.

Two phase 3 studies of oral tofacitinib in patients with moderate to severe plaque psoriasis: 16-week efficacy and safety results. The introduction of biologic therapy in the last decade represented a major advance in the treatment of patients with moderate to severe psoriasis because it achieved a better response and was associated with lower toxicity than the systemic treatments previously used. 3 study investigating tofacitinib for the treatment of psoriatic arthritis, Oral Pso. XELJANZ is approved in more than 45 countries around the world for the treatment of moderate to severe RA as a second-line therapy after failure of one or more disease-modifying antirheumatic drugs (DMARDs).

Psoriasis: Overview, Recent Approvals, Therapies On The Horizon

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015. Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis. Twelve weeks of treatment with tofacitinib had no clinically significant effects on CMV or EBV viral load, suggesting that lymphocyte sub-populations critical to the response to chronic viral infections and viral reactivation were not significantly affected.

Two Phase 3 Studies Of Oral Tofacitinib In Patients With Moderate To Severe Plaque Psoriasis: 16-week Efficacy And Safety Results